Stentys to Present Bifurcated Stent Data at PCR
May 16, 2007 — Stentys has announced that the results of preclinical testing of its bifurcated stent will be reported on Thursday, May 24, 2007, at the "EuroPCR 2007" Cardiovascular Congress in Barcelona, Spain next week as part of the "Innovative Emerging Technologies" program.
Stentys is the first company to develop the next-generation of dedicated drug-eluting stents for treatment of blocked coronary artery bifurcations so that hundreds of thousands of patients might avoid open-chest surgery.
The patent-pending innovation of Stentys' bifurcated stent is that the stent-opening for the side branch can be created anywhere in the stent after it is implanted in the vessel. In short, the procedure's success is independent from accurate positioning.
The Stentys procedure is performed in three steps: (1) Stentys is implanted in the main vessel with an approximate positioning, like a standard stent; (2) the cardiologist chooses the optimal location for the side branch opening by inserting a balloon through the stent mesh, which is a cath lab-standard procedure; and, (3) the balloon inflation disconnects the mesh and creates the opening — the Stentys approach allows the in situ modeling of the stent to fit the patient's unique arterial anatomy.
For more information visit .www.stentys.com.